^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Serotonin reuptake inhibitor

    Related drugs:
    3d
    Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea (clinicaltrials.gov)
    P4, N=45, Completed, China Medical University Hospital | Recruiting --> Completed | N=132 --> 45
    Trial completion • Enrollment change
    3d
    Duloxetine for LBP (clinicaltrials.gov)
    P4, N=120, Recruiting, Montefiore Medical Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    5d
    Characterization and Prognostic Impact of Fascin Expression in the Tumor Microenvironment of Triple-Negative Breast Cancer: Clues for a Tailored Therapy. (PubMed, Lab Invest)
    These findings highlight the dual role of fascin in tumor cells and the tumor microenvironment (TME), and reinforce its potential as a biomarker for personalized TNBC therapies. Ongoing clinical trials, including HITCLIF, are exploring the efficacy of imipramine in patients with fascin-overexpressing cancers, paving the way for targeted treatment strategies.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BCL2 (B-cell CLL/lymphoma 2) • FSCN1 (Fascin Actin-Bundling Protein 1)
    |
    HER-2 expression
    |
    imipramine
    6d
    A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels (clinicaltrials.gov)
    P1, N=174, Completed, Otsuka Pharmaceutical Development & Commercialization, Inc.
    New P1 trial
    17d
    Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis (clinicaltrials.gov)
    P3, N=44, Recruiting, Tanta University | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    18d
    The Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia (clinicaltrials.gov)
    P=N/A, N=384, Recruiting, Beijing Tiantan Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    18d
    The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia (clinicaltrials.gov)
    P=N/A, N=400, Recruiting, Beijing Tiantan Hospital
    New trial
    21d
    Duloxetine RCT on Postop TKA Outcomes (clinicaltrials.gov)
    P4, N=241, Completed, Rush University Medical Center | Recruiting --> Completed | N=504 --> 241 | Trial completion date: Nov 2025 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date
    21d
    Experimental study on the treatment of norepinephrine transporter-overexpressing pheochromocytomas and paragangliomas: a synthetic lethality strategy combining 131I-MIBG with PARP inhibitors. (PubMed, Front Oncol)
    This study aims to investigate the therapeutic potential of 131I-MIBG and the PARP inhibitor fluzoparib monotherapies and their combination on two distinct PC12-derived stable cell lines: PC12-NET cells and PC12-NET-SDHB cells...The specificity of PC12-NET cells to the 131I-MIBG was confirmed through desipramine inhibition assays...The combined of 131I-MIBG with PARP inhibitor demonstrated a synergistic antitumor effect in PC12-NET cells. While PC12-NET-SDHB cells display comparable sensitivity to 131I-MIBG as PC12-NET cells, they exhibited heightened responsiveness to PARP inhibitor treatment.
    Journal • PARP Biomarker
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B)
    |
    AiRuiYi (fluzoparib) • Azedra (iobenguane I 131)
    29d
    Comparing Effectiveness of Duloxetine and Desipramine in Patients With Chronic Pain: A Pragmatic Trial Using Point of Care Randomization (clinicaltrials.gov)
    P4, N=86, Completed, Stanford University | Recruiting --> Completed | N=320 --> 86
    Trial completion • Enrollment change
    1m
    Duloxetine and Pregabalin for Neuropathic Cancer Pain (ACTRN12620000656932)
    P3, N=84, Terminated, University of Technology Sydney | Recruiting --> Terminated
    Trial termination
    1m
    Deciphering the structural impact of norepinephrine analog radiopharmaceuticals on organic cation transporter affinity. (PubMed, Biomed Pharmacother)
    This study highlights the critical influence of the compounds' chemical structure on NET and OCT affinities. Structural modifications that reduce OCT-mediated uptake while maintaining high NET affinity could improve the specificity and theranostic potential of NET-targeting ligands. These findings provide insights for designing next-generation radiotracers with enhanced selectivity and clinical utility.
    Journal
    |
    SLC22A1 (Solute Carrier Family 22 Member 1) • SLC22A2 (Solute Carrier Family 22 Member 2)
    |
    Azedra (iobenguane I 131)